FPFredun Pharmaceuticals539730Warrant news

Allotment of 44,000 equity shares on conversion of 14,667 warrants

Fredun Pharmaceuticals has allotted 44,000 equity shares of face value Rs. 10/- each.

By ScoutQuest · Fri 23 Oct 2026, 6:30 PM IST · 2 min read

Equity Shares Allotted

44,000 equity shares of face value Rs. 10/- each

Warrants Converted

14,667 convertible warrants

Warrants Outstanding

No warrants are left outstanding for conversion after this allotment

The company informed the exchanges that its Board of Directors, at a meeting held on 23rd October 2026, allotted 44,000 equity shares of face value Rs. 10/- each to non-promoter allottees. The allotment follows the exercise of conversion rights attached to convertible warrants issued earlier on a preferential basis.

The transaction in short

• The warrants were allotted on December 29, 2025 on a preferential basis, pursuant to shareholder approval at an Extra-Ordinary General Meeting held on October 22, 2025.
• The warrant holders have paid the balance of the consideration and applied for conversion of 14,667 warrants into 44,000 equity shares.
• All 44,000 equity shares are fully paid-up, of face value Rs. 10/- each.
• The shares will be issued in dematerialised form and will rank pari passu with the existing equity shares of the company.
• After this allotment, the number of warrants outstanding for conversion is zero.

Price and payment structure

• Each warrant carried an issue price of Rs. 1,250/- per warrant.
• Of this, Rs. 312.50/- per warrant, being 25% of the issue price, was payable upfront.
• The allottees have since paid the applicable balance consideration, which is why the conversion could be given effect.

Why 14,667 warrants became 44,000 shares

• The company made a 1:2 bonus issue after the warrants were allotted.
• Under that adjustment, the entitlement attached to the outstanding warrants was proportionately revised.
• Each outstanding warrant became exercisable into three equity shares — that is, 14,667 outstanding warrants into 44,000 equity shares — with the exercise price revised accordingly.

Allottee-wise details

• Divya Aggarwal (non-promoter): 8,000 warrants allotted in December 2025; 2,667 equity shares allotted on conversion; 0 warrants outstanding; 8,000 shares after the effect of the 1:2 bonus issue.
• Indu Ramanlal Golecha (non-promoter): 8,000 warrants allotted in December 2025; 8,000 equity shares allotted on conversion; 0 warrants outstanding; 24,000 shares after the effect of the 1:2 bonus issue.
• Sahil Dhir (non-promoter): 4,000 warrants allotted in December 2025; 4,000 equity shares allotted on conversion; 0 warrants outstanding; 12,000 shares after the effect of the 1:2 bonus issue.
• Total: 20,000 warrants allotted in December 2025; 14,667 equity shares allotted on conversion; 0 warrants outstanding; 44,000 shares after the effect of the bonus issue.

What this means for a retail investor

• The total number of equity shares in issue rises by 44,000, which has a small proportionate effect on the holding of existing shareholders.
• The conversion is fully paid, so the balance consideration on these warrants has come into the company.
• The new shares rank pari passu with existing shares, so the allottees get the same rights as other shareholders.
• The allotment closes out the entire block of 14,667 warrants that were outstanding for conversion.

The Board meeting commenced at 03:00 p.m. and concluded at 05:45 p.m.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev